Company Profile

iXpressGenes Inc (AKA: Proteomics)
Profile last edited on: 11/4/19      CAGE: 4FXF0      UEI: TSJKJXX5GNN8

Business Identifier: Artificial genes
Year Founded
2009
First Award
2008
Latest Award
2017
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

601 Genome Way
Huntsville, AL 35806
   (256) 426-0413
   info@ixpressgenes.com
   www.ixpressgenes.com
Location: Single
Congr. District: 05
County: Madison

Public Profile

Located at the HudsonAlpha Institute for Biotechnology in Huntsville AL, iXpressGenes is a synthetic biology company offering service to commercial, institutional and academic organizations. Disciplines respresented amng ersoonel include biochemistry, structural genomics and instrumentation. The firm specializes in protein services and instrumentation, and protein and genetic engineering research. With the principals having background in extremozymes, microgravity and trace fluorescent labeling, iXpressGenes has exclusive access to a suite of hyperthermophilic genomes from the deep sea vents of the Atlantic Ridge. Proteins and enzymes from these genomes have special qualities that are useful in engineering and metabolic reactions. Having assembed a team that is deeply experienced in microgravity the firm has conducted several experiments on the International Space Station. These experiments have led the firm to diffraction studies in both X ray and neutron beam. Futher, years of research in protein crystallization ha enabled the firm to develop a new, . highly effective technique to support our finding and discerning leads - trace fluorescent labeling.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2017 2 CBD $1,143,714
Project Title: Producing Novel Biosynthetic Therapeutics from Extreme Microbiomes
2017 2 NIH $1,108,277
Project Title: Macromolecule Crystallization Screening Results Analysis
2014 2 NIH $843,506
Project Title: Fluorescence Intensity-Based Scoring of Macromolecule Crystallization Plates
2011 2 NIH $844,435
Project Title: Fluorescence Anisotropy-Based Macromolecule Crystallization Screening

Key People / Management

  Lance Larka -- Chief Operations Officer, Chief Technologist

  Joseph D Ng

  Marc Lee Pusey

  Anuj Singhal

Company News

There are no news available.